-+ 0.00%
-+ 0.00%
-+ 0.00%

AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 BASKET TRIAL OF EBRIBAFUSP IN RARE COMPLEMENT-MEDIATED KIDNEY DISEASES

Reuters·09/14/2026 12:00:00

Please log in to view news